Study of 246 axSpA (nraxSpA 82, r-axSpA 164) w/ Sxduration 26 yrs. axSpA had more comorbid Dz (^CCI) esp for uveitis (28 vs 1%), IBD (10 v 1%), PsO (10 v 3%)], CVD (7 v 3%), FM (12 v 3%). BUT NO DIFF between r-axSp & nraxSpA for comorbidities https://t.co/0ERLt083yq https://t.co/65x02ZFKTb